and Evenity has the potential to reduce fracture risk in patients at high risk due to a prior fracture. “We look forward to continuing our work with the FDA to demonstrate the benefit ...

UCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a regulatory rejection, to become the first new drug for the condition since ...